Beacon Hill Medical Pharmacy Recalls Glycyrrhizic Acid Injectable Due to Sterility Concerns
Beacon Hill Medical Pharmacy is recalling Glycyrrhizic Acid 8 mg/mL Injectable because FDA inspectional findings raised concerns about sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable product, which poses a risk of serious injury or hospitalization due to potential infection.
Plain-English summary
Beacon Hill Medical Pharmacy, P.C. is recalling Glycyrrhizic Acid 8 mg/mL Injectable, all presentations, for intravenous and subcutaneous use. The recall was initiated following FDA inspectional findings that resulted in concerns associated with quality control procedures impacting sterility assurance.
The product was compounded by Beacon Hill Medical Pharmacy PC, dba Rxtra Solutions, in Southfield, MI. The recall covers the product distributed nationwide in the USA. Specific lot numbers identified in the recall include 03072013@18, 04152013@27, and 04112013@12.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or healthcare provider for further instructions. The FDA has classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- GLYCYRRHIZIC ACID 8 MG/ML INJECTABLE, all presentations, FOR INTRAVENO and SQ USE ONLY, STERILE, RX ONLY, Compounded by Beacon Hill Medical Pharmacy PC, dba Rxtra Solutions, Southfield, MI
- Manufacturer
- Beacon Hill Medical Pharmacy, P.C.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- 03072013@18
- 04152013@27
- 04112013@12
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 86 recalled by Beacon Hill Medical Pharmacy, P.C. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Beacon Hill Medical Pharmacy, P.C.
See all →- SevereBeacon Hill Medical Pharmacy Recalls B-12 Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- HighBeacon Hill Medical Pharmacy Recalls Sermorelin Acetate Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Potassium Chloride Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereBeacon Hill Medical Pharmacy Recalls Multitrace-5 Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SeverePromise Pharmacy Recalls Glycyrrhizic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- HighTailor Made Compounding Recalls Glycyrrhizic Acid Injectable for Lack of Sterility Assurance
FDA (Drugs) · 2022-07-20
- HighInjectable Glycerin Sterile Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-01
- SevereFDA Recalls PGE Injectable Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-01-15
- HighBuprenorphine Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2023-02-01
- SevereAdvanced Pharma Recalls Glycopyrrolate Injectable Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27